Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
Taysha Gene Therapies announced new preclinical data showing that its scAAV9 vector enables approximately 30-fold higher MeCP2 protein expression compared to single-stranded vectors in neuronal cell models. The data also confirms that the miniMeCP2 protein used in TSHA-102 is functionally comparable to the full-length protein, validating the therapy's construct design.
Key figures
- Drug Name
- TSHA-102
- Phase Of Trial
- Phase 1/2
- Rett prevalence range
- 15,000 to 20,000
- Expression increase fold
- 30-fold
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.